GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (FRA:CPH) » Definitions » Total Liabilities

Histogen (FRA:CPH) Total Liabilities : €1.32 Mil (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Histogen Total Liabilities?

Histogen's Total Liabilities for the quarter that ended in Sep. 2023 was €1.32 Mil.

Histogen's quarterly Total Liabilities declined from Mar. 2023 (€5.35 Mil) to Jun. 2023 (€4.87 Mil) and declined from Jun. 2023 (€4.87 Mil) to Sep. 2023 (€1.32 Mil).

Histogen's annual Total Liabilities declined from Dec. 2020 (€6.66 Mil) to Dec. 2021 (€6.25 Mil) and declined from Dec. 2021 (€6.25 Mil) to Dec. 2022 (€5.38 Mil).


Histogen Total Liabilities Historical Data

The historical data trend for Histogen's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen Total Liabilities Chart

Histogen Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Liabilities
36.82 6.66 6.25 5.38

Histogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.99 5.38 5.35 4.87 1.32

Histogen Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Histogen's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.165+(4.138+1.8041124150159E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.075+0)
=5.38

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=18.005-12.627
=5.38

Histogen's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.263+(0+1.6653345369377E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.061+0)
=1.32

Total Liabilities=Total Assets (Q: Sep. 2023 )-Total Equity (Q: Sep. 2023 )
=5.451-4.127
=1.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Histogen Total Liabilities Related Terms

Thank you for viewing the detailed overview of Histogen's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Histogen (FRA:CPH) Business Description

Traded in Other Exchanges
Address
10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Histogen (FRA:CPH) Headlines

No Headlines